Polyrizon to explore revenue-generating real asset opportunities

Polyrizon’s (PLRZ) Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets. The company said, “The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products such as PL-14, PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery. In parallel, leveraging the Company’s strong cash position, the Board has authorized the exploration of investments in assets that are expected to generate revenues and create additional value for shareholders. This strategic initiative aims to efficiently utilize the Company’s resources to accelerate growth and deliver long-term shareholder value, while maintaining full focus on the primary medical pipeline.”